TY - JOUR
T1 - A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus
AU - Brandler Grolleau, Samantha
AU - Ruffie, Claude
AU - Combredet, Chantal
AU - Brault, Jean-Baptiste
AU - Najburg, Valerie
AU - Prevost, Marie Christine
AU - Habel, Andre
AU - Tauber, Erich
AU - Despres, Philippe
AU - Tangy, Frederic
PY - 2013
Y1 - 2013
N2 - Chikungunya virus (CHIKV), a mosquito-transmitted alphavirus, recently reemerged in the Indian Ocean, India and Southeast Asia, causing millions of cases of severe polyarthralgia. No specific treatment to prevent disease or vaccine to limit epidemics is currently available. Here we describe a recombinant live-attenuated measles vaccine (MV) expressing CHIKV virus-like particles comprising capsid and envelope structural proteins from the recent CHIKV strain La Reunion. Immunization of mice susceptible to measles virus induced high titers of CHIKV antibodies that neutralized several primary isolates. Specific cellular immune responses were also elicited. A single immunization with this vaccine candidate protected all mice from a lethal CHIKV challenge, and passive transfer of immune sera conferred protection to naive mice. Measles vaccine is one of the safest and most effective human vaccines. A recombinant MV-CHIKV virus could make a safe and effective vaccine against chikungunya that deserves to be further tested in human trials
AB - Chikungunya virus (CHIKV), a mosquito-transmitted alphavirus, recently reemerged in the Indian Ocean, India and Southeast Asia, causing millions of cases of severe polyarthralgia. No specific treatment to prevent disease or vaccine to limit epidemics is currently available. Here we describe a recombinant live-attenuated measles vaccine (MV) expressing CHIKV virus-like particles comprising capsid and envelope structural proteins from the recent CHIKV strain La Reunion. Immunization of mice susceptible to measles virus induced high titers of CHIKV antibodies that neutralized several primary isolates. Specific cellular immune responses were also elicited. A single immunization with this vaccine candidate protected all mice from a lethal CHIKV challenge, and passive transfer of immune sera conferred protection to naive mice. Measles vaccine is one of the safest and most effective human vaccines. A recombinant MV-CHIKV virus could make a safe and effective vaccine against chikungunya that deserves to be further tested in human trials
UR - http://www.sciencedirect.com.ezproxy.lib.monash.edu.au/science/article/pii/S0264410X13007019#
U2 - 10.1016/j.vaccine.2013.05.086
DO - 10.1016/j.vaccine.2013.05.086
M3 - Article
VL - 31
SP - 3718
EP - 3725
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 36
ER -
